 
Biocon Limited 
20th KM, Hosur Road 
Electronic City  
Bangalore 560 100, India 
T 91 80 2808 2808 
F 91 80 2852 3423 
 
CIN : L24234KA1978PLC003417 
 
www.biocon.com  
BIO/SECL/TG/2025-26/123 
 
November 19, 2025 
 
To               
The Manager, 
BSE Limited 
Department of Corporate Services 
Phiroze Jeejeebhoy Towers,  
Dalal Street, Mumbai – 400 001 
To    
The Manager, 
National Stock Exchange of India Limited 
Corporate Communication Department 
Exchange Plaza, Bandra Kurla Complex  
Mumbai – 400 050 
Scrip Code - 532523 Scrip Symbol - Biocon 
 
Subject: Notification to Stock Exchanges  
 
Dear Sir/Madam, 
 
This is to inform you that Biocon Pharma Limited, a wholly owned subsidiary of the Company, has received 
approval from the U.S Food and Drug Administration (U.S. FDA) for its ANDA for Tofacitinib Extended-
Release Tablets. Final approval received for 11mg strength and  tentative approval  for 22mg strength. 
Tofacitinib extended-release tablets are a Janus kinase (JAK) inhibitor  indicated for Rheumatoid Arthritis, 
Psoriatic Arthritis, Ankylosing Spondylitis and Ulcerative Colitis. 
 
The approval will further strengthen Biocon’s portfolio of vertically integrated, complex drug products. 
 
Kindly take the same on record and acknowledge. 
 
Thanking You,  
 
Yours faithfully, 
 
For Biocon Limited 
 
 
_________________ 
Rajesh U. Shanoy 
Company Secretary and Compliance Officer 
M. No.: ACS 16328 
 
